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Abstract
Background: Oats provide important nutritional and pharmacological properties, although their safety in
coeliac patients remains controversial. Previous studies have confirmed that the reactivity of the anti-33-mer
monoclonal antibody with different oat varieties is proportional to the immune responses in terms of T-cell
proliferation. Although the impact of these varieties on the adaptive response has been studied, the role of the
dendritic cells (DC) is still poorly understood. The aim of this study is to characterize different oat fractions
and to study their effect on DC from coeliac patients.
Methods and results: Protein fractions were isolated from oat grains and analyzed by SDSPAGE. Several
proteins were characterized in the prolamin fraction using immunological and proteomic tools, and by Nano-
LC-MS/MS. These proteins, analogous to a- and g-gliadin-like, showed reactive sequences to anti-33-mer
antibody suggesting their immunogenic potential. That was further confirmed as some of the newly identified
oat peptides had a differential stimulatory capacity on circulating DC from coeliac patients compared with
healthy controls.
Conclusions: This is the first time, to our knowledge, where newly identified oat peptides have been shown to
elicit a differential stimulatory capacity on circulating DC obtained from coeliac patients, potentially
identifying immunogenic properties of these oat peptides.
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C
oeliac disease (CD) is an autoimmune disorder
developed in genetically (HLADQ2/8) predis-
posed individuals and caused by a permanent
intolerance to gluten contained in some cereals, such as
wheat, rye, and barley, that lead to a chronic inflamma-
tion of the small intestine (13).
The most accepted model for explaining CD immuno-
pathogenesis is the two-signal model (4) characterized by a
first innate immune response followed by a secondary
antigen-specific adaptive response. Some peptides like the
19-mer gliadin peptide trigger an innate immune response
(5) mainly characterized by the production of IL-15 by
epithelial cells. The result is the disruption of the epithelial
barrier, by increasing the permeability and inducing
enterocyte apoptosis (6). As a consequence, immuno-
adaptive peptides, like the 33-mer gliadin peptide, can
now reach the lamina propria where they are deaminated
by the enzyme tissue transglutaminase. Such deamidation
provides a negative load to gliadin peptides and hence
enhance their affinity to fit in the HLA-DQ2/8 bound,
which is also the ‘susceptibility gene’ in CD, expressed on
the surface of dendritic cells (DC) (79). DC are indeed the
most potent antigen-presenting cells of the immune system
as they promote differentiation of pro-inflammatory
antigen-specific effector T-cell at the time that they also
direct them to the target tissue via homing marker
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imprinting (10, 11). DC are therefore central in CD
pathogenesis as they present a gluten antigen to T-cells
(12) driving progression of the pro-inflammatory antigen-
specific adaptive immune response which will turn into the
symptomatology of the disease.
The gluten-free diet (GFD) is the basis of all the present
treatments for CD, after which the immune response is
abrogated leading to clinical remission of the disease (13,
14). Recently, the gluten-free products market has wit-
nessed a revolution due to an increased incidence of CD
coupled with the fact that it is not only coeliac and gluten-
sensitive patients consuming these products but also
individuals not affected by those pathologies (15). There-
fore, oats are of particular interest to all GFD consumers
because they could improve the nutritional value of the
GFD given their rich nutritional value and a considerably
high protein concentration. Oats also contain a number of
important minerals, lipids, b-glucan, a mixed-linkage
polysaccharide, which forms an important part of oat
dietary fiber, and also contains various other phytocon-
stituents. Finally, oats also have different pharmacological
activities including antioxidant, anti-inflammatory, anti-
diabetic, anticholesterolemic, and many others. Therefore,
all these properties have led to wider appreciation of oats
as valuable human food (16).
Studies on the suitability of oats for patients with CD
showed contradictory results. While some studies sug-
gested that oats are safe for CD patients (1720), others
have revealed that oats can trigger an immune reaction in
these patients (18, 2123), including activation of mucosal
T-cells and subsequent gut inflammation ultimately lead-
ing to villous atrophy (22). Indeed, CD patients have
circulating anti-avenin antibodies (24, 25), while a recent
study revealed that dietary oats altered the mRNA
immune status of the intestinal mucosa suggesting T-cell
activation and leaky tight junctions (26). These contra-
dictory results regarding oats safety for CD patients might
be explained by the fact that the oat varieties used in the
different studies were different. Oats include numerous
varieties, differing in the prolamin genes and hence in the
resulting amino acid sequences showing different immu-
noreactivities associated with toxic prolamins (27, 28). In
previous studies, our group has reported the utility of the
G12 monoclonal antibody (moAb) against the main
immunogenic epitope of the a-2 gliadin, 33-mer peptide,
for detecting oat varieties that are potentially toxic for CD
patients. Indeed, the reactivity with the anti-33-mer moAb
of the different oat varieties correlated with T-cell pro-
liferation and interferon gamma production of blood
T-cells isolated from such patients (29).
In the present study, we have characterized the different
protein fractions of oat prolamins and have identified
several reactive sequences to anti-33-mer moAb, analo-
gous to a- and g-gliadin-like, with immunogenic potential
for CD patients. Moreover, some of the peptides from
these subunits, obtained from Nano-LC-MS/MS data,
induced specific activation of circulating DC obtained
from CD patients on the GFD, as opposed to those from
healthy controls (HC), confirming therefore their immu-
nogenic potential.
Materials and methods
Oat sample preparation
Oats (Avena sativa L.) from cultivars designated OE717,
OA729, OM719, OC723, OH727, and OL715 (obtained
from Spanish and Australian commercial sources) were
used in this work. These cultivars were chosen based on
their previously reported CD toxicity (29).
DNA extraction
DNA extraction from oat seeds was performed using a
modified cetyltrimethylammonium bromide (CTAB)
method. DNA concentrations were determined by UV
absorption. The purity of the DNA solution was assessed
by the 260/280 nm absorption ratio. Oligonucleotides
from wheat, barley, rye, and oats were used. This protocol
and oligonucleotides have been characterized in detail in
previous studies from our laboratory (29).
Protein extraction and quantification
Oat flours were prepared by grinding the dehusked kernels.
Wholemeal flour (100 mg) was used for the sequential
extraction of the albumins, globulins, avenins, and glute-
nins according to Osborne (30) and Marion et al. (31).
Albumin extraction
The albumins were extracted with cold water with con-
tinuous mixing at 48C for 90 min. The mixture was
centrifuged (8,000g, 20 min) and the proteins in the
supernatant were precipitated with two volumes of acetone
at 208C. The pellet was then washed three times with
acetone and dried at room temperature.
Globulin extraction
Globulins were extracted from the pellet with a salt
solution (Tris-HCl 50 mM, NaCl 1 M, pH 8.5) in contin-
uous mixing at 48C for 1 h 30 min. Similarly, the mixture
was centrifuged and the proteins in the supernatant were
recovered with acetone.
Avenins extraction
To extract avenins, three washes were performed with cold
water on the pellet described above for 5 min with con-
tinuous vortexing. The samples were treated with 70%
ethanol (v/v) for 60 min with continuous mixing, followed
by centrifugation (10,000g, 5 min). This step was repeated
three times to remove most of the avenins. The super-
natants were pooled and incubated overnight at 658C to
recover the avenins.
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Glutenins extraction
The glutenins in the pellet were extracted and reduced
with 50% propanol-1-ol solution containing 1% w/v
dithiothreitol (DTT) for 30 min with continuous mixing
at 658C, followed by centrifugation (10,000g, 5 min) (32).
SDSPAGE
Proteins (albumins, globulins, avenins, and glutenins) were
resuspended in SDSpolyacrylamide gel electrophoresis
(PAGE) loading buffer (45 mM Tris-HCl, pH 6.8, 50 mM
DTT, 1% SDS, 10% glycerol, 0.001% bromophenol blue).
Protein concentration was determined by Bradford assay
(33). Proteins were separated by SDSPAGE using 12.5%
polyacrylamide gel using a Hoefer tank (GE Healthcare,
Little Chalfont, Buckinghamshire, UK). Gels were stained
with Coomassie Brilliant Blue (CBB).
Acid PAGE
In order to identify a large number of avenins according
to their relative mobility, an acid PAGE (A-PAGE) was
performed following the method of Branlard et al. (34).
2-DE
For further characterization of avenins, two biological
extracts with two replicates per extract were used. Iso-
electric focusing (IEF) was performed using the IPGPhor
II apparatus (GE Healthcare) on 13 cm Immobiline dry
strips of 310 linear pH gradients. Passive re-hydration
was performed overnight in a solution containing 7 M
urea, 2 M thiourea, 70 mM DTT, 1% IPG buffer (pH
310), 4% CHAPS, 0.34% anti-protease, and 100 mg
(analytical gel) or 1 mg (preparative gel) of the protein
extract. IEF was carried out by applying a cumulative
voltage of 30 and 60 kVh for analytical and preparative gel,
respectively.
Following IEF, proteins were reduced for 15 min in an
equilibration buffer containing 0.05 M Tris-HCl (pH 8.8),
6 M urea, 30% glycerol, 2% SDS, and 1% DTT, followed
by alkylation for 15 min in the same buffer containing
2.5% iodoacetamide instead of DTT. The second dimen-
sion was performed using SDSPAGE gels (12% T, 2.1%
C) sealed with 0.5% agarose in SDS buffer on Hoefer
vertical system (GE Healthcare). The migration condi-
tions were 10 mA/gel for first 30 min then 35 mA/gel until
the exit of the dye front. Gels were stained with CBB.
Immunoblotting
For immunoblot analysis, protein samples were separated
on a 12.5% SDSPAGE or a 2-DE gel and then transferred
onto a nitrocellulose membrane using a Hoefer TE77
semidry transfer blotter. The blotted membrane was
incubated for 60 min at room temperature in blocking
buffer consisting of 10 mM Tris-HCl (pH 7.6), 150 mM
NaCl, 0.01% Tween 20 and 5% skimmed milk and then
exposed to G12 moAb.
Anti-mouse IgG alkaline phosphatase A3562 and kit
SIGMA fast (ref F4523) were used for detection accord-
ing to the manufacturer instructions.
Gel images of 300 dpi and 16-bit grayscale pixel depth
were obtained with G-800 (GE Healthcare) scanner and
were analyzed using SameSpots v3.2 (Nonlinear Dy-
namics, Newcastle, UK). SameSpots applies highly accu-
rate pixel-level alignment so that 2-D gels with secondary
stained images including antibodies can be directly
compared.
In-gel digestion
Protein spots were excised from gels and de-stained with a
solution containing 25 mM NH4HCO3, 5% ACN for
30 min and 25 mM NH4HCO3 50% ACN twice for
30 min. After dehydration in 100% ACN for 10 min, the
spots were dried. Briefly, 100 ng of chymotrypsin (Sigma,
St. Louis, MO, USA), solution in Tris-HCl 100 mM, pH
7.8, CaCl2 10 mM was added to the spots and digestion
was performed at 378C for 45 h. After centrifugation,
peptides were extracted by adding 8 mL of ACN.
Nano-LC-MS/MS analysis and database searching
For Nano-LC-ESI-MS/MS analysis, peptides mixtures
were analyzed by online nanoflow liquid chromato-
graphy using the Ultimate 3000 RSLC (Dionex, Voisins
le Bretonneux, France) with nanocapillary columns of 15 cm
length75 mm ID, 3 mm, 100A˚ (Acclaim PepMap100 C18,
Dionex). The solvent gradient increased linearly from
4 to 50% acetonitrile in 0.5% formic acid at a flow rate of
300 nL/min for 30 min. The elute was then electrosprayed
in positive-ion mode at 2.7 kV in a LTQ-VELOS mass
spectrometer (Thermo Fisher Scientific, Courtaboeuf,
France) through a nanoelectrospray ion source which was
operated in a CID top 10 mode (i.e. one full scan MS
and the 10 major peaks in the full scan were selected for
MS/MS). Full-enhanced-scan MS spectra were acquired
with 1 microscan (m/z 3001,800). Dynamic exclusion was
used with one repeat count and 50 sec exclusion duration.
For MS/MS, isolation width for ion precursor was fixed
at 2 m/z, and single-charged species were rejected; frag-
mentation used 37% normalized collision energy as the
default activation of 0.25.
Protein and peptide sequence analysis
Raw data files were processed using version Peaks 5.3
software with the EBI database (Taxonomy Viridiplantae,
1,023,819 entries). The following parameters were con-
sidered for the searches: Parent Mass Error Tolerance of
1.5 Da, Fragment Mass Error Tolerance of 0.8 Da, a
maximum of one missed cleavage, and partial methionine
oxidation and partial carbamidomethylation of cysteine.
If the peaks score was statistically significant (pB0.05),
the protein was considered valid. When proteins were
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identified from only two peptides, spectra were checked
to assess their validity.
Synthesis of peptides
Different peptides derived from avenin sequences ob-
tained from the MS/MS data (Table 1) were supplied by
Biomedal S.L. (Seville, Spain).
DC from peripheral blood
Human peripheral bloodwas collected from three HC with
no known autoimmune or inflammatory diseases, aller-
gies, or malignancies and three patients with CD following
informed consent. All CD patients had been on a GFD for
at least 6 months and had no clinical symptoms or positive
serology at the time of sample taking. The study was
approved by the ethic committee of St Thomas’ Hospital,
London (United Kingdom) and written informed consent
was obtained.
Peripheral blood mononuclear cells (PBMC) were
obtained by centrifugation over Ficoll-Paque Plus (Amer-
sham Biosciences, Chalfont St. Giles, UK). Human
bloodenriched DC were subsequently enriched following
NycoPrepTM centrifugation of overnight cultured PBMC
in complete medium Dutch modified RPMI 1640 (Sigma-
Aldrich, Dorset, UK) containing 100 U/mL penicillin/
streptomycin, 2 mM L-glutamine, 50 mg/mL gentamicin
(Sigma-Aldrich), and 10% fetal calf serum (TCS Cell-
works, Buckingham, UK). This protocol has been char-
acterized in detail in previous studies as a way to obtain
fresh human bloodenriched DC (3538). Blood-enriched
DC were further cultured for 24 h in complete medium in
the presence of oat peptides, 33-mer peptide, STp (peptide
secreted by Lactobacillus plantarum) or LPS (lipopolysac-
charide from Escherichia coli) (Sigma-Aldrich, St. Louis,
MO, USA). The same molar concentration was used for all
peptides to avoid the problem of epitope load between
large and small peptides. Results were referred with a
paired culture in basal medium which acted as an internal
control.
Proliferation assay
Freshly obtained PBMC from HC were suspended in
MiniMACs buffer (PBS containing 0.5% BSA and 2 mM
EDTA). T-cells were enriched by depletion of CD14,
CD19, and HLA-DR-positive cells with immunomagnetic
beads (Miltenyi Biotech, Bisley, UK) following manufac-
turer’s instructions. An average of 94.91%91.06 (mean9
SD) T-cells was obtained following enrichment. T-cells
were labeled with 10 mM 5-carboxyfluorescein diacetate
succinimidyl ester (CFSE, Invitrogen Ltd, Paisley, UK)
following manufacturer’s instructions. CFSE-labeled T-cells
(4105/well) were incubated for 5 days in U-bottomed
96-well microtiter plates with allogeneic blood DC at
0, 1, or 3%. Cells were washed twice in FACS buffer, fixed
with 1% paraformaldehyde in 0.85% saline, and stored at
48C prior to acquisition.
Flow cytometry and data analysis
Cells were acquired on a FACSCantoII (BD Biosciences)
flow cytometer (within 48 h). Data were analyzed using
WinList 5.0 software (Verity, Topsham, Maine, USA). The
percentage of proliferating T-cells was assessed via CFSE
dilution of viable cells based on their forward and size
properties as previously described (11).
Statistical analysis
Results were analyzed in the GraphPad Prism statistical
PC program (GraphPad Prism 6.0 Software, San Diego,
CA) using two-way and one-way repeated measures
ANOVA, and two-tailed paired tests. P-valueB0.05 was
considered significant.
Results and discussion
Protein characterization in different oat varieties
Protein fractions from six oat varieties previously de-
scribed as potentially reactive for CD patients (29) were
studied by SDSPAGE. The purity of the oat seeds was
tested by a visual examination, and PCR experiments
discarded the presence of wheat, rye, and barley DNA in
the samples. The protein patterns of these cereals were
compared with those of gliadins (from wheat) and with a
pre-stained molecular weight marker (Fig. 1a).
Proteins with a wide range of molecular weights ranging
fromB20 to 80 kDa were found in all albumin fractions of
the different cultivars. Oat albumins, which are considered
to be primarily enzymes, are a minor component with
values ranging from 1 to 12% of total protein (39).
Nevertheless, most of the protein fraction from the oat
grains was soluble in buffered salt solutions and thus
classified as globulins (40). These proteins (Fig. 1a) were
mainly of two families, the first ranging from 20 to 37 kDa,
and the second grouping around 50 kDa. Globulins
appeared with the same distribution in all cultivars
studied. Opposed to wheat gliadins, which have a typical
size range of 2970 kDa, oat avenins were smaller in size
ranging from 20 to 36 kDa with weaker bands around
5070 kDa. Another important feature of these proteins is
Table 1. Peptides derived from avenin sequences
Peptide Sequence
Gliadin-like avenins
QL6 QPQLQL
QQ6 QPQLQQ
PV10 PYPEQQEPFV
EF27 EQYQPYPEQQEPFVQQQPPFVQQEQPF
Glutenin-like avenins
QL14 QQPFMQQQPFMQPL
QM27 QYQPYPEQQPFMQQQQPFMQPLLQQQM
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that their protein patterns were diverse, confirming that
polymorphism of avenin patterns was more heterogeneous
than in the globulin fraction.
Concerning the glutenin fraction, a wide range in the
molecular weight, ranging from 50 to even lower than 20
kDa, was also observed for these proteins. For all other
accessions, the glutenin protein patterns showed a diver-
sity and heterogeneity in both size and intensity of the
subunits. Our findings confirmed therefore that oat grains
contain a significant protein fraction that is insoluble in
alcohol and soluble in denaturing/reducing solution
composed mainly of low molecular weight glutenin sub-
units (LMW-GS)-like proteins (41).
Because of the diversity found in the alcohol-soluble
fractions, in order to identify the relative mobility of these
proteins, an acid PAGE (A-PAGE) was performed. The
diversity of cereal prolamins is usually better resolved by
using electrophoresis in aluminum lactate buffer (such as
in A-PAGE). Moreover, A-PAGE allows oat prolamins to
be separated according to the ratio ionic charge/molecular
mass resulting in a better resolution as compared to the
classic SDSPAGE procedure. A large number of avenin
subunits were observed (Fig. 1b). Differences in the band
patterns were found for the studied varieties, showing a
great diversity in the composition of avenins among the
different cultivars. These results therefore confirm the
presence of different avenins in the cultivars as they differ
in both their size and ionic charge in acid pH. However,
Spanish varieties OH727 and OC723 shared the same
pattern of bands by A-PAGE. Likewise, two Australian
accessions, OE717 and OM719, kept the same prolamin
pattern but differed in two protein bands obtained in the
lower region of the gel. These accessions probably have
the same progenitors or related progenitors, or they may
have independently evolved from accessions with small
differences between them.
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Fig. 1. Protein pattern from six oat accessions. (a) Oat proteins (albumins, globulins, avenins, and glutelins) were analyzed by
SDSPAGE using 12.5% polyacrylamide gel and stained with Coomassie Brilliant Blue (CBB). (b) Avenins were analyzed by
A-PAGE gel and stained with CBB. Oat accessions: OE717, OA729, OM719, OC723, OH727, and OL715. Lane MW, molecular
weight markers (in kDa).
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Evaluating immunotoxic proteins in the alcohol-soluble
fraction from oat seeds
In order to get further insights into the proteomic and
immunological properties of the avenin proteins previously
described, and their implications in CD pathogenesis, we
focused on accession OE717 as it was described with high
immunogenic effect of CD patients (29). The avenin extract
from this accession was studied by western blot using
staining techniques which reveal in the membrane at the
same time both the antibody-recognized proteins and
the total proteins as separated by SDSPAGE. A dual
staining, first with the moAb and then nigrosin, distin-
guished the total avenin fraction versus specific proteins
(Fig. 2). Reactive proteins appeared in the region of 2537
kDa (major bands according to results obtained by SDS
PAGE); however, anti-33-mer moAb also recognized other
minority oat prolamins with higher molecular weights. The
latter may be avenin dimers and/or oat prolamins not yet
labeled with higher molecular weights.
When avenins from OE717 variety were separated in
more detail by 2-DE, a single band on 1-DE typically
yielded more than one protein spot (Fig. 3a). Avenin
fraction was separated by 2-DE and made visible by CBB
staining. The 2-DE gels of these proteins revealed spots
with relative molecular masses ranging from 35 to 20 kDa
and a pI between 3 and 10. Figure 3b showed proteome
map obtained after immunoblotting by anti-33mer
moAb. Immunoreactive spots were observed ranging
from 40 to 25 kDa on the western blot.
Among all the identified bands and spots, we next
focused on the most reactive one as revealed by their
immunoblotting intensity (Fig. 2b and 3b). Following
overlaying of the nigrosin-stained membrane, the immu-
noblot and the corresponding CBB stained gel, bands
(1-DE) and spots (2-DE) (as revealed by G12 moAb from
the CBB stained gel) were excised and mass spectrometry
analysis subsequently applied. A total of 16 reactive
proteins were identified, all belonging to the family of
prolamins, specifically avenin proteins (Table 2). We
further confirmed by BLAST searches, using Multiple
Protein Alignment Tool algorithms, that all the proteins
identified belong to fractions previously termed a- and g-
gliadin-like. However, some bands and spots could not be
identified due to lack of information from oat proteins in
available databases.
Fig. 2. Electrophoresis and immunoblot analysis of avenin
protein extracts from oat accession OE717. (a) Proteins were
separated by SDSPAGE using 12.5% polyacrylamide gel
and stained with Coomassie Brilliant Blue (CBB), (b) then
transferred onto a nitrocellulose membrane and then ex-
posed to G12 moAb. (c) Dual double membrane staining,
first using G12 moAb and then nigrosin, distinguished the
total avenin fraction versus G12-specific proteins. Lane MW,
molecular weight markers (in kDa).
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Fig. 3. Bi-dimensional analysis of avenin protein extracts from oat accession OE717. (a) Proteins were separated by isoelectric
focusing (IEF) and SDSPAGE, and then stained using Coomassie Brilliant Blue (CBB). (b) 2-D gel electrophoresis was
transferred onto a nitrocellulose membrane and exposed to G12 moAb. Lane 1-D: avenin protein extract separated by SDS
PAGE. Lane MW, molecular weight markers (in kDa).
Isabel Comino et al.
6
(page number not for citation purpose)
Citation: Food & Nutrition Research 2016, 60: 30324 - http://dx.doi.org/10.3402/fnr.v60.30324
Table 2. List of identified proteins from 1-D and 2-D gels of avenin protein extract from oat accession OE717
Samplea Accession Cov (%) Peptides Mass Description
A6 TR:G8ZCU1_9POAL 60 4 27344.3008 G8ZCU1 Avenin protein (Fragment) OSAvena prostrata GNavenin PE4 SV1
TR:G8ZCT4_9POAL 59 4 29672.8789 G8ZCT4 Avenin protein (Fragment) OSAvena longiglumis GNavenin PE4 SV1
TR:F2Q9W5_AVESA 53 3 31613.2422 F2Q9W5 Avenin protein (Fragment) OSAvena sativa GNavenin PE4 SV1
SP:AVEF_AVESA 100 2 5213.6143 Q09097 Avenin-F (Fragment) OSAvena sativa PE1 SV1
A7 TR:F2Q9W5_AVESA 55 6 31613.2422 F2Q9W5 Avenin protein (Fragment) OSAvena sativa GNavenin PE4 SV1
TR:Q09072_AVESA 61 6 25471.4941 Q09072 Avenin (Precursor) OSAvena sativa PE2 SV1
TR:G8ZCU1_9POAL 57 6 27344.3008 G8ZCU Avenin protein (Fragment) OSAvena prostrata GNavenin PE4 SV1
TR:G8ZCT1_9POAL 51 4 28834.0137 G8ZCT avenin protein (Fragment) OEAvena strigosa GNavenin PE4 SV1
SP:AVEE_AVESA 66 3 21036.1562 Q09114 Avenin-E OSAvena sativa PE1 SV1
TR:G8ZCT5_9POAL 53 4 28018.0723 G8ZCT5 Avenin protein (Fragment) OSAvena damascena GNavenin PE4 SV1
TR:G8ZCT6_9POAL 53 4 28018.0723 G8ZCT6 Avenin protein (Fragment) OSAvena strigosa GNavenin PE4 SV1
TR:G8ZCT7_9POAL 53 4 28018.0723 G8ZCT7 Avenin protein (Fragment) OSAvena canariensis GNavenin PE4 SV1
TR:G8ZCV9_9POAL 57 4 26660.6230 G8ZCV9 Avenin protein (Fragment) OSAvena murphyi GNavenin PE4 SV1
TR:G8ZCW4_9POAL 57 3 24318.9219 G8ZCW4 Avenin protein (Fragment) OSAvena macrostachya GNavenin PE4 SV1
TR:F2Q9W3_AVESA 52 2 25732.9043 F2Q9W3 Avenin protein (Fragment) OSAvena sativa GNavenin PE4 SV1
TR:G8ZCW2_9POAL 16 2 23778.5078 G8ZCW2 Avenin protein (Fragment) OSAvena ventricosa GNavenin PE4 SV1
TR:G8ZCW5_9POAL 16 2 23778.5078 G8ZCW5 Avenin protein (Fragment) OSAvena murphyi GNavenin PE4 SV1
TR:G8ZCV7_9POAL 16 2 24500.3652 G8ZCV7 Avenin protein (Fragment) OSAvena magna GNavenin PE4 SV1
TR:G8ZCV8_9POAL 16 2 24500.3652 G8ZCV8 Avenin protein (Fragment) OSAvena mnurphyi GNavenin PE4 SV1
A8 TR:G8ZCW3_9POAL 52 6 27387.3730 G8ZCW3 Avenin protein (Fragment) OSAvena insularis GNavenin PE4 SV1
TR:G8ZCT8_9POAL 50 6 28205.2715 G8ZCT8 Avenin protein (Fragment) OSAvena canariensis GNavenin PE4 SV1
TR:G8ZCT9_9POAL 50 6 28205.2715 G8ZCT9 Avenin protein (Fragment) OSAvena strigosa GNavenin PE4 SV1
TR:F2Q9W5_AVESA 45 6 31613.2422 F2Q9W5 Avenin protein (Fragment) OSAvena sativa GNavenin PE4 SV1
TR:G8ZCU1_9POAL 45 6 27344.3008 G8ZCU1 Avenin protein (Fragment) OSAvena prostrata GNavenin PE4 SV1
TR:G8ZCU6_9POAL 45 4 24307.0723 G8ZCU6 Avenin protein (Fragment) OSAvena prostrata GNavenin PE4 SV1
TR:G8ZCT2_9POAL 44 4 24435.2031 G8ZCT2 Avenin protein (Fragment) OSAvena prostrata GNavenin PE4 SV1
TR:F2Q9W4_AVESA 48 4 24631.5215 F2Q9W4 Avenin protein (Fragment) OSAvena sativa GNavenin PE4 SV1
SP:AVEE_AVESA 52 4 21036.1562 Q09114 Avenin-E OSAvena sativa PE1 SV1
TR:Q09072_AVESA 53 4 25471.4941 Q09072 Avenin (Precursor) OSAvena satival PE2 SV1
TR:G8ZCW4_9POAL 42 4 24318.9219 G8ZCW4 Avenin protein (Fragment) OSAvena macrostachya GNavenin PE4 SV1
TR:F4MJY1_AVESA 40 4 25600.3555 F4MJY1 Avenin protein (Fragment) OSAvena sativa GNavenin PE2 SV1
TR:G8ZCW0_9POAL 37 4 26011.8594 G8ZCW0 Avenin protein (Fragment) OSAvena murphyi GNavenin PE4 SV1
TR:G8ZCU2_9POAL 55 4 24137.8320 G8ZCU2 Avenin protein (Fragment) OSAvena longiglumis GNavenin PE4 SV1
TR:G8ZCU3_9POAL 55 4 24137.8320 G8ZCU3 Avenin protein (Fragment) OSAvena strigosa GNavenin PE4 SV1
TR:G8ZCU4_9POAL 55 4 24111.7949 G8ZCU4 Avenin protein (Fragment) OSAvena strigosa GNavenin PE4 SV1
TR:G8ZCU5_9POAL 44 4 23093.7402 G8ZCU5 Avenin protein (Fragment) OSAvena longiglumis GNavenin PE4 SV1
A9 SP:AVE3_AVESA 60 7 25275.4844 P80356 Avenin-3 OSAvena sativa PE1 SV1
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Table 2. (Continued )
Samplea Accession Cov (%) Peptides Mass Description
TR:Q2EPY2_AVESA 65 7 24258.3320 Q2EPY2 Avenin OSAvena sativa PE4 SV1
TR:G8ZCU1_9POAL 51 6 27344.3008 G8ZCU1 Avenin protein (Fragment) OSAvena prostrata GNavenin PE4 SV1
TR:G8ZCW3_9POAL 54 6 27387.3730 G8ZCW3 Avenin protein (Fragment) OSAvena insularis GNavenin PE4 SV1
SP:AVEE_AVESA 66 5 21036.1562 Q09114 Avenin-E OSAvena sativa PE1 SV1
TR:Q09072_AVESA 51 4 25471.4941 Q09072 Avenin (Precursor) OSAvena sativa PE2 SV1
TR:G8ZCV7_9POAL 62 4 24500.3652 G8ZCV7 Avenin protein (Fragment) OSAvena magna GNavenin PE4 SV1
TR:G8ZCV8_9POAL 53 4 24500.3652 G8ZCV8 Avenin protein (Fragment) OSAvena murphyi GNavenin PE4 SV1
TR:G8ZCU0_9POAL 54 4 23039.7891 G8ZCU0 Avenin pratein (Fragment) OSAvena damascena GNavenin PE4 SV1
TR:G8ZCW4_9POAL 51 5 24318.9219 G8ZCW4 Avenin protein (Fragment) OSAvena macrostachya GNavenin PE4 SV1
TR:G8ZCW0_9POAL 45 5 26011.8594 G8ZCW0 Avenin protein (Fragment) OSAvena murphyi GNavenin PE4 SV1
AS1 TR:G8ZCU1_9POAL 57 10 27344.3008 G8ZCU1 Avenin protein (Fragment) OSAvena prostrataa GNavenin PE4 SV1
TR:F2Q9W5_AVESA 50 9 31613.2422 F2Q9W5 Avenin protein (Fragment) OSAvena sativa GNavenin PE4B SV1
TR:G8ZCT1_9POAL 53 6 28834.0137 G8ZCT1 Avenin protein (Fragment) OSAvena strigosa GNavenin PE4 SV1
SP:AVEF_AVESA 84 3 5213.6143 Q09097 Avenin-F (Fragment) OSAvena sativa PE1 SV1
AS3 TR:F2Q9W5_AVESA 48 6 31613.2422 F2Q9W5 Avenin protein (Fragment) OSAvena sativa GNavenin PE4 SV1
TR:G8ZCU1_9POAL 50 6 27344.3008 G8ZCU1 Avenin protein (Fragment) OSAvena prostrata GNavenin PE4 SV1
TR:G8ZCW4_9POAL 51 6 24318.9219 G8ZCW4 Avenin protein (Fragment) OSAvena macrostachya GNavenin PE4 SV1
TR:F4MJY1_AVESA 57 6 25600.3555 F4MJY1 Aveninl protein (Fragment) OSAvena sativa GNavenin PE2 SV1
TR:G8ZCW0_9POAL 56 6 26011.8594 G8ZCW0 Avenin protein (Fragment) OSAvena murphyi GNavenin PE4 SV1
TR:Q09072_AVESA 55 4 25471.4941 Q09072 Avenin (Precursor) OSAvena sativa PE2 SV1
SP:AVEE_AVESA 55 5 21036.1562 Q09114 Avenin-E OSAvena sativa PE1 SV1
SP:AVEF_AVESA 67 3 5213.6143 Q09097 Avenin-F (Fragment) OSAvena sativa PE1 SV1
aSamples obtained from the 1-D and 2-D gel spots.
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Circulating DC from CD patients react to avenin peptides
CD pathogenesis is driven both by the innate and the
adaptive immune system (1, 4, 42). Although the impact
of gluten peptides on the adaptive immune system has
been studied in much detail, the role of the innate immune
response cells, including monocytes/macrophages and
DC, is still poorly understood.
DC are key actors in the connection between innate
immunity and adaptive immunity responses. Furthermore,
they are described as ‘decision makers’ to commit toler-
ance or immunity (12, 43), yet information on DC in CD
pathogenesis is scarce (8, 4447). Moreover, most of the
studies which have investigated the effect of gliadin and/or
its derived peptides on DC phenotype and/or function
have usually focused on monocyte-derived DC, generated
following 57 in vitro culture of monocytes in the presence
of IL-4 and GM-CSF (4853), which although essential
to further our understanding of human DC do not
always resemble the properties of circulating DC (54, 55).
Moreover, these studies usually focus on the effect of
gliadin and/or its derived peptides on monocyte-derived
DC from HC, usually avoiding a comparison with those
obtained from CD patients. Contrary to those studies, here
we decided to study the effect of these newly identified no-
wheat oat peptides on circulating DC obtained from both
HC and CD patients.
To determine the stimulatory capacity of the novel oat
peptides, DC were pulsed with peptides QL6, QQ6, PV10,
EF27, QL14, and QM27 of different sizes that were found
having a homology to gliadin-like avenins (Table 1) and
glutenin-like avenins. These peptides had proline-rich
sequences and glutamine residues resembling wheat gluten
sequences. Peptides PV10 and EF27 also carried a T-cell
epitope recognized by CD4 T-cells previously described
by Sollid et al. (56): DQ2.5-ave-1a epitope with glutamic
acid to glutamine conversion at position 6. As positive
control for stimulation, DC were pulsed with 33-mer
peptide, the immunodominant antigen for CD (57) or
Fig. 4. Identification of dividing T-cells after dendritic cell stimulations. Blood CFSE-labeled T-cells (400,000) from healthy
controls (HC) were cultured for 5 days with different doses (0, 1, and 3%) of allogeneic bloodenriched DC obtained from HC
and gluten-free diet (GFD) coeliac disease patients. Live T-cells were subsequently identified by flow cytometry based on the
forward (FSC-A) and side (SSC-A) scatter properties. DC stimulatory capacity was assessed based on T-cell proliferation
determined via CFSE dilution (determined on the FITC channel) compared with unstimulated T-cells (cultured in the absence
of DC). A second negative control included the culture of CFSE-negative T-cells. Histograms are representative of several
independent experiments performed with similar results. Pooled results are displayed on the right plot.
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with LPS. In addition to the basal (unstimulated) internal
negative controls, DC were also pulsed with microbiota-
derived STp, previously described to induce regulatory
effects on DC in HC without affecting their stimulatory
capacity (38).
In order to exclude any potential effect of the ongoing
inflammation on the profile of circulating DC, and there-
fore on their peptide response following in vitro challenge,
experiments were performedwith blood-enriched DC from
HC and GFD-CD patients with no clinical symptoms and
negative serology at the time of blood extraction. Follow-
ing antigen-pulsing and subsequent co-culture with T-
cells, DC from both HC and GFD-CD patients induced
dose-dependent proliferative responses of CFSE-labeled
allogeneic T-cells (determined as CFSE dilution by
responding or dividing T-cells, Fig. 4) with no differential
effect produced by blood DC from the groups irrespective
of any differential basal stimulatory status between the
groups.
The effect of the previously newly identified non-wheat
oat peptides on DC from both HC and GFD-CD patients
was studied next (Fig. 5). LPS increased stimulatory
capacity of blood DC derived from both HC and GFD-
CD while STp did not induce any change in DC
stimulatory status as previously described (Fig. 5) (38).
When pulsed with the immunodominant 33-mer peptide,
DC from both HC and GFD-CD patients increased their
stimulatory capacity for T-cells in agreement with previous
observations of an ‘ex-vivo’ gluten-challenge biopsy-
culture model (58). Having confirmed that in vitro pulsing
modulates DC stimulatory capacity from both HC and
GFD-CD patients, we studied whether the newly identified
oat peptides displayed any differential effect on DC from
the groups. Our findings revealed that oat peptides could
be divided into three groups based on 1) their lack of
stimulatory effect on DC (peptides QL6 and QQ6);
2) increase of DC stimulatory capacity from both HC
and GFD-CD patients (peptides EF27 and QM27); and
3) peptides which specifically upregulated DC stimulatory
capacity from GFD-CD patients but not from HC
(peptides PV10 and QL14). A closer look into these oat
peptides’ properties revealed that peptides QL6 and QQ6
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Fig. 5. Effect of oat peptides on the stimulatory capacity of DCs for allogeneic T-cells in CD. DC stimulatory capacity for
CFSE-labeled allogeneic T-cells was determined as in Fig. 4. DC stimulatory capacity from both gluten-free diet coeliac patients
(GFD, red lines) and healthy controls (HC, blue lines) was determined following 24-h pulsing with different stimuli as detailed in
the graphs. Two-way ANOVA repeated was applied on pulsed DC (GFD or HC) compared with their basal paired counterparts.
P-values B0.05 were considered as statistically significant (*pB0.05; **pB0.01; ***pB0.001).
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(which did not have any stimulatory effect) were the
smallest of the studied peptides (each with six residues).
On the contrary, peptides EF27 and QM27 (which induced
proliferative responses of T-cells stimulated by both HC
and GFD-CD) were larger peptides (each with 27 resi-
dues); these peptides were of a size similar to the 33-mer
peptide which had also activated DC from both HC and
GFD-CD patients. This is in agreement with similar
observations where large gliadin-derived peptides induced
DC activation from non-CD patients (49, 50, 52). Finally,
peptides PV10 and QL14 were unique in their capacity to
specifically activate DC from GFD-CD patients but not
those from HC. In contrast to the two other groups,
peptides PV10 and QL14 had intermediate sizes (PV10: 10
residues; QL14: 14 residues). These differences between the
differential stimulatory capacity of the peptides on DC
from HC and GFD-CD are not likely to be due to different
epitope loads derived from their differential size as DC
pulsing was performed at the same molar concentration.
It seems, therefore, that DC capacity to trigger T-cell
proliferative responses is not only dependent on the source
of the peptides but also on their size and their possible
differential intracellular processing. Thus, small peptides
like QL6 and QQ6 (six residues each) would fail to acti-
vate DC while large gluten peptides (peptides EF27 and
QM27  of 27 and 33 residues, respectively) would induce
DC maturation in both HC and GFD-CD. Nevertheless,
gluten peptides with the appropriate size and disposition
of amino acidspeptides PV10 (10 residues) and/or QL14
(14 residues) are likely to go through a differential en-
docytic pathway which may end in a different peptide
processing capacity elicited by DC from HC and CD
patients. Future studies will identify the specific mechan-
isms which make circulating DC form CD patients unique
on their capacity to process and present these intermediate
peptides to the T-cells, which may therefore provide valu-
able information for development of novel biomarkers
for CD diagnosis and/or monitoring. Indeed, given that
intestinal DC are likely to be derived from their circulating
precursors (59) it is quite likely that intestinal DC will also
display such differential processing capacity. If so, a deeper
characterization of the differential peptide processing
capacity elicited by intestinal DC from CD patients and
non-CD controls may provide novel information regard-
ing CD pathogenesis which may lead to development of
novel therapies for such patients.
Conclusions
Our findings exhibited the structural complexity and large
differences among oat proteins. More specifically, we
showed that oats is composed of a large number of avenin
subunits. These proteins belong to fractions termed a- and
g-gliadin-like and some of which were reactive for anti-33-
mer moAb. Moreover, our study has shown the existence
of new potentially toxic peptides for coeliac patients. These
peptides were able to activate circulating DC from coe-
liac patients, identifying, therefore, their immunogenic
properties.
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